American Portfolios Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

American Portfolios Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$69.2K	Sell	2,044 -329	-14%	-$10.7K	﹤0.01%	1535
2022 Q2	$68.6K	Buy	2,373 +22	+0.9%	+$630	﹤0.01%	1598
2022 Q1	$76K	Buy	2,351 +143	+6%	+$4.38K	﹤0.01%	1670
2021 Q4	$64.4K	Buy	2,208 +907	+70%	+$27.5K	﹤0.01%	1750
2021 Q3	$34.7K	Buy	1,301 +158	+14%	+$4.24K	﹤0.01%	1981
2021 Q2	$35.2K	Buy	+1,143	New	+$35K	﹤0.01%	1916
2020 Q1	–	Sell	-400	Closed	-$9.49K	–	2907
2019 Q4	$9.49K	Hold	400	–	–	﹤0.01%	2021
2019 Q3	$11K	Hold	400	–	–	﹤0.01%	1898
2019 Q2	$13.2K	Hold	400	–	–	﹤0.01%	1816
2019 Q1	$14K	Buy	+400	New	+$14.9K	﹤0.01%	1707
2018 Q4	–	Sell	-4,660	Closed	-$235K	–	2557
2018 Q3	$235K	Buy	4,660 +228	+5%	+$11.3K	0.03%	524
2018 Q2	$265K	Buy	+4,432	New	+$230K	0.04%	440

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Portfolios Advisors's SUPN Position: Q3 2022 in Review

American Portfolios Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 14% in Q3 2022, selling an estimated $10.7K and leaving 2,044 shares worth $69.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

American Portfolios Advisors first reported a position in SUPN in Q2 2018 and has held it in 12 quarters since. The position peaked at $265K in Q2 2018. 244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

American Portfolios Advisors held 2,044 shares of Supernus Pharmaceuticals worth $69.2K as of Q3 2022.
American Portfolios Advisors sold 329 Supernus Pharmaceuticals shares in Q3 2022, an estimated $10.7K.
Supernus Pharmaceuticals made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #1535 holding.
American Portfolios Advisors first reported a position in Supernus Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
American Portfolios Advisors's Supernus Pharmaceuticals position peaked at $265K in Q2 2018.
244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.